Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
27,461
archived clinical trials in
Hematology

A Study of Elotuzumab in Combination With Pomalidomide and Low Dose Dexamethasone and Elotuzumab in Combination With Nivolumab in Patients With Multiple Myeloma Relapsed or Refractory to Prior Treatment With Lenalidomide.
A Phase 2, Multiple Cohort Study of Elotuzumab in Combination With Pomalidomide and Low-Dose Dexamethasone (EPd), and in Combination With Nivolumab (EN), in Patients With Multiple Myeloma Relapsed or Refractory to Prior Treatment With Lenalidomide.
Status: Enrolling
Updated:  1/31/2018
Local Institution
mi
from
Germantown, TN
A Study of Elotuzumab in Combination With Pomalidomide and Low Dose Dexamethasone and Elotuzumab in Combination With Nivolumab in Patients With Multiple Myeloma Relapsed or Refractory to Prior Treatment With Lenalidomide.
A Phase 2, Multiple Cohort Study of Elotuzumab in Combination With Pomalidomide and Low-Dose Dexamethasone (EPd), and in Combination With Nivolumab (EN), in Patients With Multiple Myeloma Relapsed or Refractory to Prior Treatment With Lenalidomide.
Status: Enrolling
Updated: 1/31/2018
Local Institution
mi
from
Germantown, TN
Click here to add this to my saved trials
A Study of Elotuzumab in Combination With Pomalidomide and Low Dose Dexamethasone and Elotuzumab in Combination With Nivolumab in Patients With Multiple Myeloma Relapsed or Refractory to Prior Treatment With Lenalidomide.
A Phase 2, Multiple Cohort Study of Elotuzumab in Combination With Pomalidomide and Low-Dose Dexamethasone (EPd), and in Combination With Nivolumab (EN), in Patients With Multiple Myeloma Relapsed or Refractory to Prior Treatment With Lenalidomide.
Status: Enrolling
Updated:  1/31/2018
SCRI Tennessee Oncology Nashville
mi
from
Nashville, TN
A Study of Elotuzumab in Combination With Pomalidomide and Low Dose Dexamethasone and Elotuzumab in Combination With Nivolumab in Patients With Multiple Myeloma Relapsed or Refractory to Prior Treatment With Lenalidomide.
A Phase 2, Multiple Cohort Study of Elotuzumab in Combination With Pomalidomide and Low-Dose Dexamethasone (EPd), and in Combination With Nivolumab (EN), in Patients With Multiple Myeloma Relapsed or Refractory to Prior Treatment With Lenalidomide.
Status: Enrolling
Updated: 1/31/2018
SCRI Tennessee Oncology Nashville
mi
from
Nashville, TN
Click here to add this to my saved trials
A Study of Elotuzumab in Combination With Pomalidomide and Low Dose Dexamethasone and Elotuzumab in Combination With Nivolumab in Patients With Multiple Myeloma Relapsed or Refractory to Prior Treatment With Lenalidomide.
A Phase 2, Multiple Cohort Study of Elotuzumab in Combination With Pomalidomide and Low-Dose Dexamethasone (EPd), and in Combination With Nivolumab (EN), in Patients With Multiple Myeloma Relapsed or Refractory to Prior Treatment With Lenalidomide.
Status: Enrolling
Updated:  1/31/2018
Texas Oncology (Loop) - USOR
mi
from
Arlington, TX
A Study of Elotuzumab in Combination With Pomalidomide and Low Dose Dexamethasone and Elotuzumab in Combination With Nivolumab in Patients With Multiple Myeloma Relapsed or Refractory to Prior Treatment With Lenalidomide.
A Phase 2, Multiple Cohort Study of Elotuzumab in Combination With Pomalidomide and Low-Dose Dexamethasone (EPd), and in Combination With Nivolumab (EN), in Patients With Multiple Myeloma Relapsed or Refractory to Prior Treatment With Lenalidomide.
Status: Enrolling
Updated: 1/31/2018
Texas Oncology (Loop) - USOR
mi
from
Arlington, TX
Click here to add this to my saved trials
A Study of Elotuzumab in Combination With Pomalidomide and Low Dose Dexamethasone and Elotuzumab in Combination With Nivolumab in Patients With Multiple Myeloma Relapsed or Refractory to Prior Treatment With Lenalidomide.
A Phase 2, Multiple Cohort Study of Elotuzumab in Combination With Pomalidomide and Low-Dose Dexamethasone (EPd), and in Combination With Nivolumab (EN), in Patients With Multiple Myeloma Relapsed or Refractory to Prior Treatment With Lenalidomide.
Status: Enrolling
Updated:  1/31/2018
Virginia Cancer Specialists (Leesburg) - USOR
mi
from
Leesburg, VA
A Study of Elotuzumab in Combination With Pomalidomide and Low Dose Dexamethasone and Elotuzumab in Combination With Nivolumab in Patients With Multiple Myeloma Relapsed or Refractory to Prior Treatment With Lenalidomide.
A Phase 2, Multiple Cohort Study of Elotuzumab in Combination With Pomalidomide and Low-Dose Dexamethasone (EPd), and in Combination With Nivolumab (EN), in Patients With Multiple Myeloma Relapsed or Refractory to Prior Treatment With Lenalidomide.
Status: Enrolling
Updated: 1/31/2018
Virginia Cancer Specialists (Leesburg) - USOR
mi
from
Leesburg, VA
Click here to add this to my saved trials
A Study of Elotuzumab in Combination With Pomalidomide and Low Dose Dexamethasone and Elotuzumab in Combination With Nivolumab in Patients With Multiple Myeloma Relapsed or Refractory to Prior Treatment With Lenalidomide.
A Phase 2, Multiple Cohort Study of Elotuzumab in Combination With Pomalidomide and Low-Dose Dexamethasone (EPd), and in Combination With Nivolumab (EN), in Patients With Multiple Myeloma Relapsed or Refractory to Prior Treatment With Lenalidomide.
Status: Enrolling
Updated:  1/31/2018
Swedish Medical Center
mi
from
Seattle, WA
A Study of Elotuzumab in Combination With Pomalidomide and Low Dose Dexamethasone and Elotuzumab in Combination With Nivolumab in Patients With Multiple Myeloma Relapsed or Refractory to Prior Treatment With Lenalidomide.
A Phase 2, Multiple Cohort Study of Elotuzumab in Combination With Pomalidomide and Low-Dose Dexamethasone (EPd), and in Combination With Nivolumab (EN), in Patients With Multiple Myeloma Relapsed or Refractory to Prior Treatment With Lenalidomide.
Status: Enrolling
Updated: 1/31/2018
Swedish Medical Center
mi
from
Seattle, WA
Click here to add this to my saved trials
A Study of Elotuzumab in Combination With Pomalidomide and Low Dose Dexamethasone and Elotuzumab in Combination With Nivolumab in Patients With Multiple Myeloma Relapsed or Refractory to Prior Treatment With Lenalidomide.
A Phase 2, Multiple Cohort Study of Elotuzumab in Combination With Pomalidomide and Low-Dose Dexamethasone (EPd), and in Combination With Nivolumab (EN), in Patients With Multiple Myeloma Relapsed or Refractory to Prior Treatment With Lenalidomide.
Status: Enrolling
Updated:  1/31/2018
Cancer Care Northwest
mi
from
Spokane, WA
A Study of Elotuzumab in Combination With Pomalidomide and Low Dose Dexamethasone and Elotuzumab in Combination With Nivolumab in Patients With Multiple Myeloma Relapsed or Refractory to Prior Treatment With Lenalidomide.
A Phase 2, Multiple Cohort Study of Elotuzumab in Combination With Pomalidomide and Low-Dose Dexamethasone (EPd), and in Combination With Nivolumab (EN), in Patients With Multiple Myeloma Relapsed or Refractory to Prior Treatment With Lenalidomide.
Status: Enrolling
Updated: 1/31/2018
Cancer Care Northwest
mi
from
Spokane, WA
Click here to add this to my saved trials
A Study of Elotuzumab in Combination With Pomalidomide and Low Dose Dexamethasone and Elotuzumab in Combination With Nivolumab in Patients With Multiple Myeloma Relapsed or Refractory to Prior Treatment With Lenalidomide.
A Phase 2, Multiple Cohort Study of Elotuzumab in Combination With Pomalidomide and Low-Dose Dexamethasone (EPd), and in Combination With Nivolumab (EN), in Patients With Multiple Myeloma Relapsed or Refractory to Prior Treatment With Lenalidomide.
Status: Enrolling
Updated:  1/31/2018
Aurora Health Care
mi
from
Burlington, WI
A Study of Elotuzumab in Combination With Pomalidomide and Low Dose Dexamethasone and Elotuzumab in Combination With Nivolumab in Patients With Multiple Myeloma Relapsed or Refractory to Prior Treatment With Lenalidomide.
A Phase 2, Multiple Cohort Study of Elotuzumab in Combination With Pomalidomide and Low-Dose Dexamethasone (EPd), and in Combination With Nivolumab (EN), in Patients With Multiple Myeloma Relapsed or Refractory to Prior Treatment With Lenalidomide.
Status: Enrolling
Updated: 1/31/2018
Aurora Health Care
mi
from
Burlington, WI
Click here to add this to my saved trials
A Study of Elotuzumab in Combination With Pomalidomide and Low Dose Dexamethasone and Elotuzumab in Combination With Nivolumab in Patients With Multiple Myeloma Relapsed or Refractory to Prior Treatment With Lenalidomide.
A Phase 2, Multiple Cohort Study of Elotuzumab in Combination With Pomalidomide and Low-Dose Dexamethasone (EPd), and in Combination With Nivolumab (EN), in Patients With Multiple Myeloma Relapsed or Refractory to Prior Treatment With Lenalidomide.
Status: Enrolling
Updated:  1/31/2018
Avera Health Care
mi
from
Warszawa,
A Study of Elotuzumab in Combination With Pomalidomide and Low Dose Dexamethasone and Elotuzumab in Combination With Nivolumab in Patients With Multiple Myeloma Relapsed or Refractory to Prior Treatment With Lenalidomide.
A Phase 2, Multiple Cohort Study of Elotuzumab in Combination With Pomalidomide and Low-Dose Dexamethasone (EPd), and in Combination With Nivolumab (EN), in Patients With Multiple Myeloma Relapsed or Refractory to Prior Treatment With Lenalidomide.
Status: Enrolling
Updated: 1/31/2018
Avera Health Care
mi
from
Warszawa,
Click here to add this to my saved trials
A Study of Elotuzumab in Combination With Pomalidomide and Low Dose Dexamethasone and Elotuzumab in Combination With Nivolumab in Patients With Multiple Myeloma Relapsed or Refractory to Prior Treatment With Lenalidomide.
A Phase 2, Multiple Cohort Study of Elotuzumab in Combination With Pomalidomide and Low-Dose Dexamethasone (EPd), and in Combination With Nivolumab (EN), in Patients With Multiple Myeloma Relapsed or Refractory to Prior Treatment With Lenalidomide.
Status: Enrolling
Updated:  1/31/2018
Regional Cancer Care Associates LLC
mi
from
Bethesda, MD
A Study of Elotuzumab in Combination With Pomalidomide and Low Dose Dexamethasone and Elotuzumab in Combination With Nivolumab in Patients With Multiple Myeloma Relapsed or Refractory to Prior Treatment With Lenalidomide.
A Phase 2, Multiple Cohort Study of Elotuzumab in Combination With Pomalidomide and Low-Dose Dexamethasone (EPd), and in Combination With Nivolumab (EN), in Patients With Multiple Myeloma Relapsed or Refractory to Prior Treatment With Lenalidomide.
Status: Enrolling
Updated: 1/31/2018
Regional Cancer Care Associates LLC
mi
from
Bethesda, MD
Click here to add this to my saved trials
Bortezomib and Thalidomide in Treating Patients With Newly Diagnosed Stage II or Stage III Multiple Myeloma
VELCADE (Bortezomib) and Thalidomide in Newly Diagnosed Patients With Multiple Myeloma
Status: Enrolling
Updated:  1/31/2018
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
mi
from
Baltimore, MD
Bortezomib and Thalidomide in Treating Patients With Newly Diagnosed Stage II or Stage III Multiple Myeloma
VELCADE (Bortezomib) and Thalidomide in Newly Diagnosed Patients With Multiple Myeloma
Status: Enrolling
Updated: 1/31/2018
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
mi
from
Baltimore, MD
Click here to add this to my saved trials
An Open-Label, Phase I/II Study of Nilotinib (Tasigna) and MEK-162 (ARRY-162) Used in Combination for Patients With Refractory or Advanced Chronic Myeloid Leukemia and Philadelphia Positive Acute Leukemia (Protocol CAMN107AUS41T)
An Open-Label, Phase I/II Study of Nilotinib (Tasigna) and MEK-162 (ARRY-162) Used in Combination for Patients With Refractory or Advanced Chronic Myeloid Leukemia and Philadelphia Positive Acute Leukemia (Protocol CAMN107AUS41T)
Status: Enrolling
Updated:  2/1/2018
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
An Open-Label, Phase I/II Study of Nilotinib (Tasigna) and MEK-162 (ARRY-162) Used in Combination for Patients With Refractory or Advanced Chronic Myeloid Leukemia and Philadelphia Positive Acute Leukemia (Protocol CAMN107AUS41T)
An Open-Label, Phase I/II Study of Nilotinib (Tasigna) and MEK-162 (ARRY-162) Used in Combination for Patients With Refractory or Advanced Chronic Myeloid Leukemia and Philadelphia Positive Acute Leukemia (Protocol CAMN107AUS41T)
Status: Enrolling
Updated: 2/1/2018
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Combination Therapy Compared With Single-Drug Therapy in Patients With Cardiac Diseases
Thalassemia Clinical Research Network - Cardiac L1/DFO Trial
Status: Enrolling
Updated:  2/1/2018
Childrens Hospital Los Angeles
mi
from
Los Angeles, CA
Combination Therapy Compared With Single-Drug Therapy in Patients With Cardiac Diseases
Thalassemia Clinical Research Network - Cardiac L1/DFO Trial
Status: Enrolling
Updated: 2/1/2018
Childrens Hospital Los Angeles
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Combination Therapy Compared With Single-Drug Therapy in Patients With Cardiac Diseases
Thalassemia Clinical Research Network - Cardiac L1/DFO Trial
Status: Enrolling
Updated:  2/1/2018
Children's Hospital
mi
from
Oakland, CA
Combination Therapy Compared With Single-Drug Therapy in Patients With Cardiac Diseases
Thalassemia Clinical Research Network - Cardiac L1/DFO Trial
Status: Enrolling
Updated: 2/1/2018
Children's Hospital
mi
from
Oakland, CA
Click here to add this to my saved trials
Combination Therapy Compared With Single-Drug Therapy in Patients With Cardiac Diseases
Thalassemia Clinical Research Network - Cardiac L1/DFO Trial
Status: Enrolling
Updated:  2/1/2018
Children's Memorial Hospital
mi
from
Chicago, IL
Combination Therapy Compared With Single-Drug Therapy in Patients With Cardiac Diseases
Thalassemia Clinical Research Network - Cardiac L1/DFO Trial
Status: Enrolling
Updated: 2/1/2018
Children's Memorial Hospital
mi
from
Chicago, IL
Click here to add this to my saved trials
Combination Therapy Compared With Single-Drug Therapy in Patients With Cardiac Diseases
Thalassemia Clinical Research Network - Cardiac L1/DFO Trial
Status: Enrolling
Updated:  2/1/2018
Children's Hospital
mi
from
Boston, MA
Combination Therapy Compared With Single-Drug Therapy in Patients With Cardiac Diseases
Thalassemia Clinical Research Network - Cardiac L1/DFO Trial
Status: Enrolling
Updated: 2/1/2018
Children's Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
Combination Therapy Compared With Single-Drug Therapy in Patients With Cardiac Diseases
Thalassemia Clinical Research Network - Cardiac L1/DFO Trial
Status: Enrolling
Updated:  2/1/2018
Weill Medical College of Cornell University
mi
from
New York, NY
Combination Therapy Compared With Single-Drug Therapy in Patients With Cardiac Diseases
Thalassemia Clinical Research Network - Cardiac L1/DFO Trial
Status: Enrolling
Updated: 2/1/2018
Weill Medical College of Cornell University
mi
from
New York, NY
Click here to add this to my saved trials
Combination Therapy Compared With Single-Drug Therapy in Patients With Cardiac Diseases
Thalassemia Clinical Research Network - Cardiac L1/DFO Trial
Status: Enrolling
Updated:  2/1/2018
Children's Hospital of Philadelphia
mi
from
Philadelphia, PA
Combination Therapy Compared With Single-Drug Therapy in Patients With Cardiac Diseases
Thalassemia Clinical Research Network - Cardiac L1/DFO Trial
Status: Enrolling
Updated: 2/1/2018
Children's Hospital of Philadelphia
mi
from
Philadelphia, PA
Click here to add this to my saved trials
AMD 3100 (Mozobil Plerixafor) to Mobilize Stem Cells for Donation
Peripheral Blood Hematopoietic Progenitor Cell Mobilization With AMD 3100 (Mozobil) in Healthy Volunteers Previously Mobilized With G-CSF
Status: Enrolling
Updated:  2/5/2018
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
AMD 3100 (Mozobil Plerixafor) to Mobilize Stem Cells for Donation
Peripheral Blood Hematopoietic Progenitor Cell Mobilization With AMD 3100 (Mozobil) in Healthy Volunteers Previously Mobilized With G-CSF
Status: Enrolling
Updated: 2/5/2018
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Click here to add this to my saved trials
Surveillance Program to Determine Product Specific Rates of Invasive Hib Disease
Surveillance for Rates of Hib Disease Among Persons 0 Through 59 Months of Age Receiving Pentacel® or Other Hib Vaccines
Status: Enrolling
Updated:  2/5/2018
Clinical Research Facility
mi
from
Albany, CA
Surveillance Program to Determine Product Specific Rates of Invasive Hib Disease
Surveillance for Rates of Hib Disease Among Persons 0 Through 59 Months of Age Receiving Pentacel® or Other Hib Vaccines
Status: Enrolling
Updated: 2/5/2018
Clinical Research Facility
mi
from
Albany, CA
Click here to add this to my saved trials
Surveillance Program to Determine Product Specific Rates of Invasive Hib Disease
Surveillance for Rates of Hib Disease Among Persons 0 Through 59 Months of Age Receiving Pentacel® or Other Hib Vaccines
Status: Enrolling
Updated:  2/5/2018
Clinical Research Facility
mi
from
Martinez, CA
Surveillance Program to Determine Product Specific Rates of Invasive Hib Disease
Surveillance for Rates of Hib Disease Among Persons 0 Through 59 Months of Age Receiving Pentacel® or Other Hib Vaccines
Status: Enrolling
Updated: 2/5/2018
Clinical Research Facility
mi
from
Martinez, CA
Click here to add this to my saved trials
Surveillance Program to Determine Product Specific Rates of Invasive Hib Disease
Surveillance for Rates of Hib Disease Among Persons 0 Through 59 Months of Age Receiving Pentacel® or Other Hib Vaccines
Status: Enrolling
Updated:  2/5/2018
Clinical Research Facility
mi
from
San Francisco, CA
Surveillance Program to Determine Product Specific Rates of Invasive Hib Disease
Surveillance for Rates of Hib Disease Among Persons 0 Through 59 Months of Age Receiving Pentacel® or Other Hib Vaccines
Status: Enrolling
Updated: 2/5/2018
Clinical Research Facility
mi
from
San Francisco, CA
Click here to add this to my saved trials
Surveillance Program to Determine Product Specific Rates of Invasive Hib Disease
Surveillance for Rates of Hib Disease Among Persons 0 Through 59 Months of Age Receiving Pentacel® or Other Hib Vaccines
Status: Enrolling
Updated:  2/5/2018
Clinical Research Facility
mi
from
Applewood, CO
Surveillance Program to Determine Product Specific Rates of Invasive Hib Disease
Surveillance for Rates of Hib Disease Among Persons 0 Through 59 Months of Age Receiving Pentacel® or Other Hib Vaccines
Status: Enrolling
Updated: 2/5/2018
Clinical Research Facility
mi
from
Applewood, CO
Click here to add this to my saved trials
Surveillance Program to Determine Product Specific Rates of Invasive Hib Disease
Surveillance for Rates of Hib Disease Among Persons 0 Through 59 Months of Age Receiving Pentacel® or Other Hib Vaccines
Status: Enrolling
Updated:  2/5/2018
Clinical Research Facility
mi
from
Aurora, CO
Surveillance Program to Determine Product Specific Rates of Invasive Hib Disease
Surveillance for Rates of Hib Disease Among Persons 0 Through 59 Months of Age Receiving Pentacel® or Other Hib Vaccines
Status: Enrolling
Updated: 2/5/2018
Clinical Research Facility
mi
from
Aurora, CO
Click here to add this to my saved trials
Surveillance Program to Determine Product Specific Rates of Invasive Hib Disease
Surveillance for Rates of Hib Disease Among Persons 0 Through 59 Months of Age Receiving Pentacel® or Other Hib Vaccines
Status: Enrolling
Updated:  2/5/2018
Clinical Research Facility
mi
from
Brighton, CO
Surveillance Program to Determine Product Specific Rates of Invasive Hib Disease
Surveillance for Rates of Hib Disease Among Persons 0 Through 59 Months of Age Receiving Pentacel® or Other Hib Vaccines
Status: Enrolling
Updated: 2/5/2018
Clinical Research Facility
mi
from
Brighton, CO
Click here to add this to my saved trials
Surveillance Program to Determine Product Specific Rates of Invasive Hib Disease
Surveillance for Rates of Hib Disease Among Persons 0 Through 59 Months of Age Receiving Pentacel® or Other Hib Vaccines
Status: Enrolling
Updated:  2/5/2018
Clinical Research Facility
mi
from
Castle Rock, CO
Surveillance Program to Determine Product Specific Rates of Invasive Hib Disease
Surveillance for Rates of Hib Disease Among Persons 0 Through 59 Months of Age Receiving Pentacel® or Other Hib Vaccines
Status: Enrolling
Updated: 2/5/2018
Clinical Research Facility
mi
from
Castle Rock, CO
Click here to add this to my saved trials
Surveillance Program to Determine Product Specific Rates of Invasive Hib Disease
Surveillance for Rates of Hib Disease Among Persons 0 Through 59 Months of Age Receiving Pentacel® or Other Hib Vaccines
Status: Enrolling
Updated:  2/5/2018
Clinical Research Facility
mi
from
Denver, CO
Surveillance Program to Determine Product Specific Rates of Invasive Hib Disease
Surveillance for Rates of Hib Disease Among Persons 0 Through 59 Months of Age Receiving Pentacel® or Other Hib Vaccines
Status: Enrolling
Updated: 2/5/2018
Clinical Research Facility
mi
from
Denver, CO
Click here to add this to my saved trials
Surveillance Program to Determine Product Specific Rates of Invasive Hib Disease
Surveillance for Rates of Hib Disease Among Persons 0 Through 59 Months of Age Receiving Pentacel® or Other Hib Vaccines
Status: Enrolling
Updated:  2/5/2018
Clinical Research Facility
mi
from
Hartford, CT
Surveillance Program to Determine Product Specific Rates of Invasive Hib Disease
Surveillance for Rates of Hib Disease Among Persons 0 Through 59 Months of Age Receiving Pentacel® or Other Hib Vaccines
Status: Enrolling
Updated: 2/5/2018
Clinical Research Facility
mi
from
Hartford, CT
Click here to add this to my saved trials
Surveillance Program to Determine Product Specific Rates of Invasive Hib Disease
Surveillance for Rates of Hib Disease Among Persons 0 Through 59 Months of Age Receiving Pentacel® or Other Hib Vaccines
Status: Enrolling
Updated:  2/5/2018
Clinical Research Facility
mi
from
Adamsville, GA
Surveillance Program to Determine Product Specific Rates of Invasive Hib Disease
Surveillance for Rates of Hib Disease Among Persons 0 Through 59 Months of Age Receiving Pentacel® or Other Hib Vaccines
Status: Enrolling
Updated: 2/5/2018
Clinical Research Facility
mi
from
Adamsville, GA
Click here to add this to my saved trials
Surveillance Program to Determine Product Specific Rates of Invasive Hib Disease
Surveillance for Rates of Hib Disease Among Persons 0 Through 59 Months of Age Receiving Pentacel® or Other Hib Vaccines
Status: Enrolling
Updated:  2/5/2018
Clinical Research Facility
mi
from
Auburn, GA
Surveillance Program to Determine Product Specific Rates of Invasive Hib Disease
Surveillance for Rates of Hib Disease Among Persons 0 Through 59 Months of Age Receiving Pentacel® or Other Hib Vaccines
Status: Enrolling
Updated: 2/5/2018
Clinical Research Facility
mi
from
Auburn, GA
Click here to add this to my saved trials
Surveillance Program to Determine Product Specific Rates of Invasive Hib Disease
Surveillance for Rates of Hib Disease Among Persons 0 Through 59 Months of Age Receiving Pentacel® or Other Hib Vaccines
Status: Enrolling
Updated:  2/5/2018
Clinical Research Facility
mi
from
Canton, GA
Surveillance Program to Determine Product Specific Rates of Invasive Hib Disease
Surveillance for Rates of Hib Disease Among Persons 0 Through 59 Months of Age Receiving Pentacel® or Other Hib Vaccines
Status: Enrolling
Updated: 2/5/2018
Clinical Research Facility
mi
from
Canton, GA
Click here to add this to my saved trials
Surveillance Program to Determine Product Specific Rates of Invasive Hib Disease
Surveillance for Rates of Hib Disease Among Persons 0 Through 59 Months of Age Receiving Pentacel® or Other Hib Vaccines
Status: Enrolling
Updated:  2/5/2018
Clinical Research Facility
mi
from
Carrollton, GA
Surveillance Program to Determine Product Specific Rates of Invasive Hib Disease
Surveillance for Rates of Hib Disease Among Persons 0 Through 59 Months of Age Receiving Pentacel® or Other Hib Vaccines
Status: Enrolling
Updated: 2/5/2018
Clinical Research Facility
mi
from
Carrollton, GA
Click here to add this to my saved trials
Surveillance Program to Determine Product Specific Rates of Invasive Hib Disease
Surveillance for Rates of Hib Disease Among Persons 0 Through 59 Months of Age Receiving Pentacel® or Other Hib Vaccines
Status: Enrolling
Updated:  2/5/2018
Clinical Research Facility
mi
from
Cartersville, GA
Surveillance Program to Determine Product Specific Rates of Invasive Hib Disease
Surveillance for Rates of Hib Disease Among Persons 0 Through 59 Months of Age Receiving Pentacel® or Other Hib Vaccines
Status: Enrolling
Updated: 2/5/2018
Clinical Research Facility
mi
from
Cartersville, GA
Click here to add this to my saved trials
Surveillance Program to Determine Product Specific Rates of Invasive Hib Disease
Surveillance for Rates of Hib Disease Among Persons 0 Through 59 Months of Age Receiving Pentacel® or Other Hib Vaccines
Status: Enrolling
Updated:  2/5/2018
Clinical Research Facility
mi
from
Conyers, GA
Surveillance Program to Determine Product Specific Rates of Invasive Hib Disease
Surveillance for Rates of Hib Disease Among Persons 0 Through 59 Months of Age Receiving Pentacel® or Other Hib Vaccines
Status: Enrolling
Updated: 2/5/2018
Clinical Research Facility
mi
from
Conyers, GA
Click here to add this to my saved trials
Surveillance Program to Determine Product Specific Rates of Invasive Hib Disease
Surveillance for Rates of Hib Disease Among Persons 0 Through 59 Months of Age Receiving Pentacel® or Other Hib Vaccines
Status: Enrolling
Updated:  2/5/2018
Clinical Research Facility
mi
from
Covington, GA
Surveillance Program to Determine Product Specific Rates of Invasive Hib Disease
Surveillance for Rates of Hib Disease Among Persons 0 Through 59 Months of Age Receiving Pentacel® or Other Hib Vaccines
Status: Enrolling
Updated: 2/5/2018
Clinical Research Facility
mi
from
Covington, GA
Click here to add this to my saved trials
Surveillance Program to Determine Product Specific Rates of Invasive Hib Disease
Surveillance for Rates of Hib Disease Among Persons 0 Through 59 Months of Age Receiving Pentacel® or Other Hib Vaccines
Status: Enrolling
Updated:  2/5/2018
Clinical Research Facility
mi
from
Cumming, GA
Surveillance Program to Determine Product Specific Rates of Invasive Hib Disease
Surveillance for Rates of Hib Disease Among Persons 0 Through 59 Months of Age Receiving Pentacel® or Other Hib Vaccines
Status: Enrolling
Updated: 2/5/2018
Clinical Research Facility
mi
from
Cumming, GA
Click here to add this to my saved trials
Surveillance Program to Determine Product Specific Rates of Invasive Hib Disease
Surveillance for Rates of Hib Disease Among Persons 0 Through 59 Months of Age Receiving Pentacel® or Other Hib Vaccines
Status: Enrolling
Updated:  2/5/2018
Clinical Research Facility
mi
from
Dallas, GA
Surveillance Program to Determine Product Specific Rates of Invasive Hib Disease
Surveillance for Rates of Hib Disease Among Persons 0 Through 59 Months of Age Receiving Pentacel® or Other Hib Vaccines
Status: Enrolling
Updated: 2/5/2018
Clinical Research Facility
mi
from
Dallas, GA
Click here to add this to my saved trials
Surveillance Program to Determine Product Specific Rates of Invasive Hib Disease
Surveillance for Rates of Hib Disease Among Persons 0 Through 59 Months of Age Receiving Pentacel® or Other Hib Vaccines
Status: Enrolling
Updated:  2/5/2018
Clinical Research Facility
mi
from
Decatur, GA
Surveillance Program to Determine Product Specific Rates of Invasive Hib Disease
Surveillance for Rates of Hib Disease Among Persons 0 Through 59 Months of Age Receiving Pentacel® or Other Hib Vaccines
Status: Enrolling
Updated: 2/5/2018
Clinical Research Facility
mi
from
Decatur, GA
Click here to add this to my saved trials
Surveillance Program to Determine Product Specific Rates of Invasive Hib Disease
Surveillance for Rates of Hib Disease Among Persons 0 Through 59 Months of Age Receiving Pentacel® or Other Hib Vaccines
Status: Enrolling
Updated:  2/5/2018
Clinical Research Facility
mi
from
Douglasville, GA
Surveillance Program to Determine Product Specific Rates of Invasive Hib Disease
Surveillance for Rates of Hib Disease Among Persons 0 Through 59 Months of Age Receiving Pentacel® or Other Hib Vaccines
Status: Enrolling
Updated: 2/5/2018
Clinical Research Facility
mi
from
Douglasville, GA
Click here to add this to my saved trials
Surveillance Program to Determine Product Specific Rates of Invasive Hib Disease
Surveillance for Rates of Hib Disease Among Persons 0 Through 59 Months of Age Receiving Pentacel® or Other Hib Vaccines
Status: Enrolling
Updated:  2/5/2018
Clinical Research Facility
mi
from
Fayetteville, GA
Surveillance Program to Determine Product Specific Rates of Invasive Hib Disease
Surveillance for Rates of Hib Disease Among Persons 0 Through 59 Months of Age Receiving Pentacel® or Other Hib Vaccines
Status: Enrolling
Updated: 2/5/2018
Clinical Research Facility
mi
from
Fayetteville, GA
Click here to add this to my saved trials
Surveillance Program to Determine Product Specific Rates of Invasive Hib Disease
Surveillance for Rates of Hib Disease Among Persons 0 Through 59 Months of Age Receiving Pentacel® or Other Hib Vaccines
Status: Enrolling
Updated:  2/5/2018
Clinical Research Facility
mi
from
Good Hope, GA
Surveillance Program to Determine Product Specific Rates of Invasive Hib Disease
Surveillance for Rates of Hib Disease Among Persons 0 Through 59 Months of Age Receiving Pentacel® or Other Hib Vaccines
Status: Enrolling
Updated: 2/5/2018
Clinical Research Facility
mi
from
Good Hope, GA
Click here to add this to my saved trials
Surveillance Program to Determine Product Specific Rates of Invasive Hib Disease
Surveillance for Rates of Hib Disease Among Persons 0 Through 59 Months of Age Receiving Pentacel® or Other Hib Vaccines
Status: Enrolling
Updated:  2/5/2018
Clinical Research Facility
mi
from
Griffin, GA
Surveillance Program to Determine Product Specific Rates of Invasive Hib Disease
Surveillance for Rates of Hib Disease Among Persons 0 Through 59 Months of Age Receiving Pentacel® or Other Hib Vaccines
Status: Enrolling
Updated: 2/5/2018
Clinical Research Facility
mi
from
Griffin, GA
Click here to add this to my saved trials
Surveillance Program to Determine Product Specific Rates of Invasive Hib Disease
Surveillance for Rates of Hib Disease Among Persons 0 Through 59 Months of Age Receiving Pentacel® or Other Hib Vaccines
Status: Enrolling
Updated:  2/5/2018
Clinical Research Facility
mi
from
Hampton, GA
Surveillance Program to Determine Product Specific Rates of Invasive Hib Disease
Surveillance for Rates of Hib Disease Among Persons 0 Through 59 Months of Age Receiving Pentacel® or Other Hib Vaccines
Status: Enrolling
Updated: 2/5/2018
Clinical Research Facility
mi
from
Hampton, GA
Click here to add this to my saved trials
Surveillance Program to Determine Product Specific Rates of Invasive Hib Disease
Surveillance for Rates of Hib Disease Among Persons 0 Through 59 Months of Age Receiving Pentacel® or Other Hib Vaccines
Status: Enrolling
Updated:  2/5/2018
Clinical Research Facility
mi
from
Jasper, GA
Surveillance Program to Determine Product Specific Rates of Invasive Hib Disease
Surveillance for Rates of Hib Disease Among Persons 0 Through 59 Months of Age Receiving Pentacel® or Other Hib Vaccines
Status: Enrolling
Updated: 2/5/2018
Clinical Research Facility
mi
from
Jasper, GA
Click here to add this to my saved trials
Surveillance Program to Determine Product Specific Rates of Invasive Hib Disease
Surveillance for Rates of Hib Disease Among Persons 0 Through 59 Months of Age Receiving Pentacel® or Other Hib Vaccines
Status: Enrolling
Updated:  2/5/2018
Clinical Research Facility
mi
from
Jonesboro, GA
Surveillance Program to Determine Product Specific Rates of Invasive Hib Disease
Surveillance for Rates of Hib Disease Among Persons 0 Through 59 Months of Age Receiving Pentacel® or Other Hib Vaccines
Status: Enrolling
Updated: 2/5/2018
Clinical Research Facility
mi
from
Jonesboro, GA
Click here to add this to my saved trials
Surveillance Program to Determine Product Specific Rates of Invasive Hib Disease
Surveillance for Rates of Hib Disease Among Persons 0 Through 59 Months of Age Receiving Pentacel® or Other Hib Vaccines
Status: Enrolling
Updated:  2/5/2018
Clinical Research Facility
mi
from
Marietta, GA
Surveillance Program to Determine Product Specific Rates of Invasive Hib Disease
Surveillance for Rates of Hib Disease Among Persons 0 Through 59 Months of Age Receiving Pentacel® or Other Hib Vaccines
Status: Enrolling
Updated: 2/5/2018
Clinical Research Facility
mi
from
Marietta, GA
Click here to add this to my saved trials
Surveillance Program to Determine Product Specific Rates of Invasive Hib Disease
Surveillance for Rates of Hib Disease Among Persons 0 Through 59 Months of Age Receiving Pentacel® or Other Hib Vaccines
Status: Enrolling
Updated:  2/5/2018
Clinical Research Facility
mi
from
Newnan, GA
Surveillance Program to Determine Product Specific Rates of Invasive Hib Disease
Surveillance for Rates of Hib Disease Among Persons 0 Through 59 Months of Age Receiving Pentacel® or Other Hib Vaccines
Status: Enrolling
Updated: 2/5/2018
Clinical Research Facility
mi
from
Newnan, GA
Click here to add this to my saved trials
Surveillance Program to Determine Product Specific Rates of Invasive Hib Disease
Surveillance for Rates of Hib Disease Among Persons 0 Through 59 Months of Age Receiving Pentacel® or Other Hib Vaccines
Status: Enrolling
Updated:  2/5/2018
Clinical Research Facility
mi
from
Annapolis, MD
Surveillance Program to Determine Product Specific Rates of Invasive Hib Disease
Surveillance for Rates of Hib Disease Among Persons 0 Through 59 Months of Age Receiving Pentacel® or Other Hib Vaccines
Status: Enrolling
Updated: 2/5/2018
Clinical Research Facility
mi
from
Annapolis, MD
Click here to add this to my saved trials
Surveillance Program to Determine Product Specific Rates of Invasive Hib Disease
Surveillance for Rates of Hib Disease Among Persons 0 Through 59 Months of Age Receiving Pentacel® or Other Hib Vaccines
Status: Enrolling
Updated:  2/5/2018
Clinical Research Facility
mi
from
Santa Fe, NM
Surveillance Program to Determine Product Specific Rates of Invasive Hib Disease
Surveillance for Rates of Hib Disease Among Persons 0 Through 59 Months of Age Receiving Pentacel® or Other Hib Vaccines
Status: Enrolling
Updated: 2/5/2018
Clinical Research Facility
mi
from
Santa Fe, NM
Click here to add this to my saved trials
Surveillance Program to Determine Product Specific Rates of Invasive Hib Disease
Surveillance for Rates of Hib Disease Among Persons 0 Through 59 Months of Age Receiving Pentacel® or Other Hib Vaccines
Status: Enrolling
Updated:  2/5/2018
Clinical Research Facility
mi
from
Albany, NY
Surveillance Program to Determine Product Specific Rates of Invasive Hib Disease
Surveillance for Rates of Hib Disease Among Persons 0 Through 59 Months of Age Receiving Pentacel® or Other Hib Vaccines
Status: Enrolling
Updated: 2/5/2018
Clinical Research Facility
mi
from
Albany, NY
Click here to add this to my saved trials
Surveillance Program to Determine Product Specific Rates of Invasive Hib Disease
Surveillance for Rates of Hib Disease Among Persons 0 Through 59 Months of Age Receiving Pentacel® or Other Hib Vaccines
Status: Enrolling
Updated:  2/5/2018
Clinical Research Facility
mi
from
Amsterdam, NY
Surveillance Program to Determine Product Specific Rates of Invasive Hib Disease
Surveillance for Rates of Hib Disease Among Persons 0 Through 59 Months of Age Receiving Pentacel® or Other Hib Vaccines
Status: Enrolling
Updated: 2/5/2018
Clinical Research Facility
mi
from
Amsterdam, NY
Click here to add this to my saved trials